These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35070018)

  • 1. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study.
    Alhinai A; Qayyum-Khan A; Zhang X; Samaha P; Metrakos P; Deschenes M; Wong P; Ghali P; Chen TY; Sebastiani G
    World J Hepatol; 2021 Dec; 13(12):2179-2191. PubMed ID: 35070018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection.
    Benmassaoud A; Ghali P; Cox J; Wong P; Szabo J; Deschenes M; Osikowicz M; Lebouche B; Klein MB; Sebastiani G
    PLoS One; 2018; 13(1):e0191985. PubMed ID: 29381754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.
    Lee HW; Park SY; Kim SU; Jang JY; Park H; Kim JK; Lee CK; Chon YE; Han KH
    PLoS One; 2016; 11(6):e0157358. PubMed ID: 27284700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population.
    Hirono H; Watanabe K; Hasegawa K; Ohkoshi S
    J Clin Transl Hepatol; 2019 Jun; 7(2):127-131. PubMed ID: 31293912
    [No Abstract]   [Full Text] [Related]  

  • 6. Nonalcoholic Fatty Liver Disease in Living Donor Liver Transplant Recipients: A Histology-Based Study.
    Choudhary NS; Saraf N; Dhampalwar S; Mishra S; Gautam D; Lipi L; Rastogi A; Bhangui P; Chaudhary RJ; Gupta A; Yadav K; Soin AS
    J Clin Exp Hepatol; 2022; 12(5):1328-1332. PubMed ID: 36157151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Kim JW; Lee CH; Kim BH; Lee YS; Hwang SY; Park BN; Park YS
    Quant Imaging Med Surg; 2022 Mar; 12(3):1815-1829. PubMed ID: 35284276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.
    Padole P; Arora A; Sharma P; Chand P; Verma N; Kumar A
    J Clin Exp Hepatol; 2022; 12(2):435-439. PubMed ID: 35535066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of a two-step approach with cytokeratin-18 and controlled attenuation parameter in noninvasive differential diagnosis of nonalcoholic steatohepatitis].
    Shen F; Zheng RD; Mi YQ; Shi JP; Wang XY; Hu XQ; Pan Q; Xu LM; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):429-34. PubMed ID: 27465946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
    Williams CD; Stengel J; Asike MI; Torres DM; Shaw J; Contreras M; Landt CL; Harrison SA
    Gastroenterology; 2011 Jan; 140(1):124-31. PubMed ID: 20858492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.
    Saroli Palumbo C; Restellini S; Chao CY; Aruljothy A; Lemieux C; Wild G; Afif W; Lakatos PL; Bitton A; Cocciolillo S; Ghali P; Bessissow T; Sebastiani G
    Inflamm Bowel Dis; 2019 Jan; 25(1):124-133. PubMed ID: 29889226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
    Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
    J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
    Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
    Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.